Decision

Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)

Doxecitine and Doxribtimine in the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 7 July 2026

Documents

Doxecitine and Doxribtimine: Public Assessment Report

PDF, 456 KB, 8 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Doxecitine and Doxribtimine: Treatment Protocol for Healthcare Professionals

PDF, 1010 KB, 31 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Doxecitine and Doxribtimine: Treatment Protocol for Patients

PDF, 1.14 MB, 22 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Doxecitine and Doxribtimine: Treatment Protocol on the Pharmacovigilance System

PDF, 155 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Doxecitine and Doxribtimine: Information for NHS Medical Directors

PDF, 438 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The scientific opinion was issued on the 02 July 2026 to UCB Pharma Limited in the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years with Doxecitine and Doxribtimine.

For the full EAMS indication please see section 4.1 of the Treatment protocol: Information for healthcare professionals.

The scientific opinion includes:

• a public assessment report (PAR)
• a treatment protocol:
  • for healthcare professionals
  • for patients
  • on the pharmacovigilance system
• Information for NHS Medical Directors

Published 7 July 2026